Recent data showed that some postmenopausal women may be able to avoid adjuvant chemotherapy. The RxPONDER study found that postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive nodes and a 21-gene RS ≥ 25 (Oncotype DX) derived no further benefit from chemotherapy that was added to endocrine therapy. However, premenopausal patients with the same clinical characteristics saw a 45% relative risk reduction in invasive disease–free survival events.
Evidence suggests that chemotherapy does offer survival benefits for women aged 70 years or older with TNBC. A recent study found that older women with TNBC who received chemotherapy had significantly improved survival compared with those who were recommended to undergo chemotherapy but did not receive it.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Fast Five Quiz: Breast Cancer Myths - Medscape - Apr 20, 2021.